Literature DB >> 20693798

Prevalence of multidrug-resistant bacteria at a tertiary-care teaching hospital in Mexico: special focus on Acinetobacter baumannii.

Elvira Garza-González1, Jorge Martín Llaca-Díaz, Francisco Javier Bosques-Padilla, Gloria M González.   

Abstract

Our aim was to determine the prevalence of multidrug resistance of Acinetobacter baumannii and other pathogens at a tertiary-care teaching hospital in Mexico over a 3-year period. Clinical isolates of A. baumannii (n = 550), Pseudomonas aeruginosa (n = 250), some Enterobacteriaceae species (n = 500) and Staphylococcus aureus (n = 250) collected over a 3-year period were included. Susceptibility tests were performed by the broth microdilution method. 74% of A. baumannii, 40% of Escherichia coli, 34% of P. aeruginosa, 22% of Klebsiella pneumoniae, 9% of Enterobacter cloacae, and 7% of Serratia sp. were multidrug resistant. 59% of A. baumannii clinical isolates were meropenem-resistant. A. baumannii isolates from the lower respiratory tract were the most susceptible, followed by urine clinical isolates. Species from Enterobacteriaceae showed susceptibility rates higher than 90% to meropenem and tigecycline and Serratia sp. showed the highest susceptibility to the drugs evaluated. For P. aeruginosa, the most potent drug was levofloxacin, followed by meropenem and piperacillin-tazobactam. With regard to S. aureus, 96% of the isolates were susceptible to vancomycin, followed by tigecycline and minocycline (91% of strains susceptible). The high multidrug resistance observed underscores the need for surveillance of bacterial drug resistance.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20693798     DOI: 10.1159/000319903

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  14 in total

1.  genetic determinants of intrinsic colistin tolerance in Acinetobacter baumannii.

Authors:  M Indriati Hood; Kyle W Becker; Christelle M Roux; Paul M Dunman; Eric P Skaar
Journal:  Infect Immun       Date:  2012-12-10       Impact factor: 3.441

2.  Rational design of α-helical antimicrobial peptides to target Gram-negative pathogens, Acinetobacter baumannii and Pseudomonas aeruginosa: utilization of charge, 'specificity determinants,' total hydrophobicity, hydrophobe type and location as design parameters to improve the therapeutic ratio.

Authors:  Ziqing Jiang; Adriana I Vasil; Lajos Gera; Michael L Vasil; Robert S Hodges
Journal:  Chem Biol Drug Des       Date:  2011-02-02       Impact factor: 2.817

3.  Loss of mitochondrial protein Fus1 augments host resistance to Acinetobacter baumannii infection.

Authors:  M Indriati Hood; Roman Uzhachenko; Kelli Boyd; Eric P Skaar; Alla V Ivanova
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

4.  Outcomes of critically ill cancer patients with Acinetobacter baumannii infection.

Authors:  Silvio A Ñamendys-Silva; Paulina Correa-García; Francisco J García-Guillén; María O González-Herrera; Américo Pérez-Alonso; Julia Texcocano-Becerra; Angel Herrera-Gómez; Patricia Cornejo-Juárez; Abelardo Meneses-García
Journal:  World J Crit Care Med       Date:  2015-08-04

5.  Identification of an Acinetobacter baumannii zinc acquisition system that facilitates resistance to calprotectin-mediated zinc sequestration.

Authors:  M Indriati Hood; Brittany L Mortensen; Jessica L Moore; Yaofang Zhang; Thomas E Kehl-Fie; Norie Sugitani; Walter J Chazin; Richard M Caprioli; Eric P Skaar
Journal:  PLoS Pathog       Date:  2012-12-06       Impact factor: 6.823

6.  "Specificity Determinants" Improve Therapeutic Indices of Two Antimicrobial Peptides Piscidin 1 and Dermaseptin S4 Against the Gram-negative Pathogens Acinetobacter baumannii and Pseudomonas aeruginosa.

Authors:  Ziqing Jiang; Adriana I Vasil; Michael L Vasil; Robert S Hodges
Journal:  Pharmaceuticals (Basel)       Date:  2014-03-25

Review 7.  Antibiotic-Resistant Acinetobacter baumannii Increasing Success Remains a Challenge as a Nosocomial Pathogen.

Authors:  Ana Maria Gonzalez-Villoria; Veronica Valverde-Garduno
Journal:  J Pathog       Date:  2016-02-04

Review 8.  Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities.

Authors:  Muhammad Asif; Iqbal Ahmad Alvi; Shafiq Ur Rehman
Journal:  Infect Drug Resist       Date:  2018-08-21       Impact factor: 4.003

9.  Ω76: A designed antimicrobial peptide to combat carbapenem- and tigecycline-resistant Acinetobacter baumannii.

Authors:  Deepesh Nagarajan; Natasha Roy; Omkar Kulkarni; Neha Nanajkar; Akshay Datey; Sathyabaarathi Ravichandran; Chandrani Thakur; Sandeep T; Indumathi V Aprameya; Siddhartha P Sarma; Dipshikha Chakravortty; Nagasuma Chandra
Journal:  Sci Adv       Date:  2019-07-24       Impact factor: 14.136

10.  Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial.

Authors:  Rayo Morfin-Otero; Eduardo Rodriguez Noriega; Michael J Dowzicky
Journal:  Ann Clin Microbiol Antimicrob       Date:  2015-12-15       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.